Quick Answer
AEON Biopharma, Inc. reported Operating Income of -$12.80 million for fiscal year 2025.
AEON Biopharma, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$12.80M | -117.5% |
| 2024 | $72.98M | +250.7% |
| 2022 | -$48.43M | -2401.6% |
| 2021 | -$1.94M | -53856.0% |
| 2020 | -$3.6K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.49M | +37.9% | +42.5% |
| June 30, 2025 | -$4.34M | -102.8% | -839.0% |
| March 31, 2025 | -$462.0K | +99.4% | +88.5% |
| September 30, 2024 | -$4.02M | +98.6% | -102.6% |
| June 30, 2024 | $153.47M | +1198.5% | +307.0% |
| March 31, 2024 | -$74.15M | -468.4% | +73.9% |
| September 30, 2023 | -$283.71M | -2762.0% | -10695.8% |
| July 31, 2023 | -$2.63M | — | +81.2% |
- AEON Biopharma, Inc. showed a decrease of -117.5% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, AEON Biopharma, Inc.’s operating income has declined by 356728.3% (from -$3.6 thousand to -$12.80 million).
- The most recent figure is from AEON Biopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: